Dentsply Sirona Inc Stock Price, News & Analysis

DENTSPLY SIRONA reported Q4 2020 revenue of $1.08 billion, down 2.6% from $1.1 billion in Q4 2019. GAAP EPS fell by 2.2% to $0.45, while non-GAAP EPS rose 19.2% to $0.87. For FY20, total revenue dropped 17.1% to $3.34 billion. Operating cash flow for FY20 remained strong at $635 million. The company announced a fiscal year 2021 outlook, projecting revenue between $4.0 billion and $4.3 billion, representing a growth of 20% to 30%. Non-GAAP EPS for FY21 is expected to range from $2.60 to $2.80.

Dentsply Sirona (Nasdaq: XRAY) has declared a quarterly cash dividend of $0.10 per share, indicating an annual rate of $0.40. The dividend will be payable on April 9, 2021 to stockholders on record as of March 26, 2021. As the largest manufacturer of professional dental products, Dentsply Sirona provides a comprehensive range of innovative solutions to enhance patient care and improve dental practices. This announcement reflects the company's ongoing commitment to returning value to its shareholders.

Dentsply Sirona (Nasdaq: XRAY) will host an investor conference call and live webcast on March 1, 2021, at 8:30 am ET. An earnings press release will be issued earlier that morning. Investors can access the call via the company’s website and participate by calling +1-877-370-7637 (domestic) or +1-629-228-0723 (international) using Conference ID # 8540717. A replay will be available for a week. Dentsply Sirona, the largest manufacturer of dental products, focuses on advancing patient care through innovative solutions.

Dentsply Sirona (Nasdaq: XRAY) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 AM ET. CEO Don Casey will represent the company during the event. Interested parties can access a live audio webcast of the presentation on their website. A replay will also be available afterward. Dentsply Sirona is the largest manufacturer of dental products and technologies, known for its innovation and quality in the dental industry, with a 132-year history.

Dentsply Sirona has acquired Byte for $1.04 billion, enhancing its position in the clear aligner market. This all-cash transaction is expected to accelerate growth and profitability in Dentsply's combined clear aligner business, with projected run-rate sales exceeding $300 million by the end of 2021. The acquisition is anticipated to be accretive to Dentsply's Non-GAAP EPS by at least $0.05 in 2021. Dentsply's CEO emphasizes the strategic importance of this deal, while Byte's management is set to continue operations under the Dentsply umbrella.

Dentsply Sirona (NASDAQ: XRAY) announced a quarterly cash dividend of $0.10 per share, indicating an annual rate of $0.40. The dividend is set for payment on January 8, 2021, to those on record by December 24, 2020. As the largest global manufacturer of professional dental products, Dentsply Sirona continues to advance dental care through its innovative products and technologies, supporting both the dental industry and patients worldwide.

Dentsply Sirona (Nasdaq: XRAY) will participate in the 2020 Wolfe Research Virtual Healthcare Conference on November 19th, 2020. CEO Don Casey will represent the company in a fireside chat scheduled for 1:45 PM Eastern Time. Investors can access the live audio webcast through the Dentsply Sirona website, where a replay will also be available. Dentsply Sirona is a leading manufacturer of dental products with a strong history of innovation, aiming to enhance patient care through effective solutions. For more details, visit www.dentsplysirona.com.

Dentsply Sirona (Nasdaq: XRAY) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, 2020. CEO Don Casey is scheduled to present at 8:45 AM ET. Investors can access a live webcast on the company's website, where a replay will also be available later. Dentsply Sirona is the largest manufacturer of professional dental products and technologies, with a strong focus on innovative solutions for patient care and dentistry.

Dentsply Sirona (Nasdaq: XRAY) reported Q3 2020 net sales of $895 million, a 7.0% decline year-over-year, with organic sales down 8.8%. GAAP operating income fell 25.4% to $82 million, while Non-GAAP operating income rose 14.3% to $197 million. GAAP EPS declined 34.2% to $0.25, although Non-GAAP EPS increased 17.5% to $0.67. Operating cash flow improved to $207 million from $159 million in 2019, and total cash on hand is $1.3 billion. The company has not provided guidance for the fiscal year due to COVID-19 uncertainties.